Contact Palatin   Site Map  
   
 
05-08-08 Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
03-10-08 Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study with PL-3994 for the Treatment of Congestive Heart Failure
02-11-08 Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
 

Palatin Technologies, Inc. (AMEX:PTN) is a biopharmaceutical company focused on discovering and developing receptor-specific small molecule and peptide therapeutics, including melanocortin (MC)-based therapeutics.

The Company is evaluating further development of bremelanotide (formerly PT-141), a MC receptor agonist, for the treatment of male and female sexual dysfunction. Palatin’s patented drug discovery platform, MIDAS™, streamlines the drug discovery process with an efficient approach to creating lead compounds based on protein conformation.